(NASDAQ: INDV) Indivior Pharmaceuticals's forecast annual revenue growth rate of 1.58% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Indivior Pharmaceuticals's revenue in 2026 is $1,332,000,000.On average, 8 Wall Street analysts forecast INDV's revenue for 2026 to be $149,877,334,230, with the lowest INDV revenue forecast at $133,827,477,966, and the highest INDV revenue forecast at $159,318,426,150. On average, 8 Wall Street analysts forecast INDV's revenue for 2027 to be $157,076,166,819, with the lowest INDV revenue forecast at $141,498,365,151, and the highest INDV revenue forecast at $166,281,231,441.
In 2028, INDV is forecast to generate $164,865,067,653 in revenue, with the lowest revenue forecast at $150,939,457,071 and the highest revenue forecast at $177,846,569,043.